HIVEP3 Inhibitors
Chemical inhibitors of HIVEP3 can affect its function through various biochemical and cellular pathways by targeting specific enzymes and signaling cascades that HIVEP3 is involved in. Cyclosporin A and FK506, for instance, are calcineurin inhibitors that prevent the activation of NFAT, a transcription factor that HIVEP3 binds to. This binding is crucial for the transcriptional activity of HIVEP3 in immune response genes. By inhibiting NFAT, these chemicals can suppress the influence HIVEP3 has on gene expression modulated through NFAT-related pathways. Similarly, Rapamycin, an mTOR inhibitor, can lead to a decrease in the activity of several transcription factors that regulate cell growth and proliferation, pathways where HIVEP3 has a functional role. The MEK inhibitors PD98059 and U0126 can obstruct the MAPK/ERK pathway, which is involved in transmitting signals that can activate HIVEP3, leading to a reduction in its transcriptional regulatory functions.
In addition, SP600125 and SB203580, which inhibit JNK and p38 MAP kinase respectively, can diminish the activity of HIVEP3 by targeting signaling pathways that regulate its function. By inhibiting JNK or p38 MAPK, these inhibitors can disrupt the signaling mechanisms that enable HIVEP3 to perform its role in gene expression regulation. PI3K inhibitors, such as LY294002 and Wortmannin, reduce the phosphorylation and activity of AKT, which in turn affects the downstream transcription factors that interact with HIVEP3, thereby inhibiting its activity in the PI3K/AKT signaling pathway. Furthermore, SN-38, by causing DNA damage responses, can alter the binding dynamics of transcription factors and co-regulators like HIVEP3, thereby indirectly inhibiting its functional activity in gene regulation. Proteasome inhibitors like Bortezomib and MG132 can disrupt the proteostasis within the cell, leading to an altered regulatory environment that affects the functional activity of HIVEP3 by changing the turnover and stability of proteins that regulate or are co-regulated by HIVEP3.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A is a calcineurin inhibitor that can functionally inhibit HIVEP3 by preventing the activation of NFAT (nuclear factor of activated T-cells), a transcription factor that HIVEP3 can bind to. This inhibition can suppress the transcriptional activity that HIVEP3 exerts through NFAT-related pathways. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
FK506 binds to the immunophilin FKBP12, forming a complex that inhibits calcineurin. By inhibiting calcineurin, FK506 can reduce the activity of NFAT, which in turn can decrease the functional activity of HIVEP3, as HIVEP3 is known to interact with NFAT in the regulation of immune response genes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin forms a complex with FKBP12, similar to FK506, but instead of inhibiting calcineurin, it inhibits mTOR. mTOR inhibition can lead to a reduced activity of several transcription factors and can indirectly inhibit HIVEP3's role in transcriptional regulation as part of signal transduction related to cell growth and proliferation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that can indirectly inhibit HIVEP3 by blocking the MAPK/ERK pathway. Since HIVEP3 is involved in transcriptional regulation following activation by pathways including the MAPK/ERK pathway, inhibition of this pathway can result in decreased functional activity of HIVEP3. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of MAPK/ERK pathway. By inhibiting this pathway, U0126 can reduce the functional activity of HIVEP3, which is implicated in the regulation of gene transcription modulated by MAPK/ERK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), a part of the MAPK pathway. By inhibiting JNK, SP600125 can indirectly inhibit HIVEP3, considering that HIVEP3's transcriptional activity can be regulated by JNK signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. Inhibition of p38 MAPK can lead to reduced HIVEP3 activity, as HIVEP3 has been shown to be functionally involved in pathways that are regulated by p38 MAPK signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it can reduce AKT phosphorylation and activity, subsequently affecting downstream transcription factors that interact with HIVEP3, leading to an inhibition of HIVEP3's functional role in these pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor and works similarly to LY294002. By inhibiting PI3K, it can indirectly inhibit the functional activity of HIVEP3 associated with the PI3K/AKT signaling pathway. | ||||||
SN 38 | 86639-52-3 | sc-203697 sc-203697A sc-203697B | 10 mg 50 mg 500 mg | $119.00 $342.00 $883.00 | 19 | |
SN-38 is the active metabolite of the topoisomerase inhibitor Irinotecan. It can lead to DNA damage responses that may alter the binding of transcription factors and co-regulators like HIVEP3, indirectly inhibiting its functional activity in gene regulation. | ||||||